Bank of America Corp DE lessened its holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 72.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 215,999 shares of the company's stock after selling 559,537 shares during the period. Bank of America Corp DE owned about 0.30% of Zentalis Pharmaceuticals worth $654,000 at the end of the most recent quarter.
Other institutional investors have also recently bought and sold shares of the company. Almitas Capital LLC raised its position in Zentalis Pharmaceuticals by 69.3% in the fourth quarter. Almitas Capital LLC now owns 1,626,896 shares of the company's stock valued at $4,929,000 after purchasing an additional 665,968 shares during the last quarter. Boxer Capital Management LLC bought a new position in shares of Zentalis Pharmaceuticals during the fourth quarter valued at $1,364,000. JPMorgan Chase & Co. lifted its holdings in shares of Zentalis Pharmaceuticals by 75.7% during the fourth quarter. JPMorgan Chase & Co. now owns 859,710 shares of the company's stock worth $2,605,000 after purchasing an additional 370,511 shares during the period. Walleye Capital LLC acquired a new stake in Zentalis Pharmaceuticals in the fourth quarter valued at $587,000. Finally, BNP Paribas Financial Markets bought a new position in Zentalis Pharmaceuticals during the 4th quarter worth $534,000.
Wall Street Analyst Weigh In
ZNTL has been the subject of a number of analyst reports. Wedbush restated a "neutral" rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Thursday, May 15th. HC Wainwright restated a "buy" rating and set a $10.00 price target on shares of Zentalis Pharmaceuticals in a report on Thursday, May 15th. Five research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, Zentalis Pharmaceuticals currently has an average rating of "Hold" and a consensus price target of $8.24.
Get Our Latest Stock Report on ZNTL
Insider Activity
In other Zentalis Pharmaceuticals news, Director Scott Dunseth Myers purchased 21,000 shares of Zentalis Pharmaceuticals stock in a transaction that occurred on Wednesday, April 30th. The stock was acquired at an average price of $1.40 per share, with a total value of $29,400.00. Following the transaction, the director now owns 281,192 shares in the company, valued at $393,668.80. This trade represents a 8.07% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.90% of the company's stock.
Zentalis Pharmaceuticals Price Performance
Shares of Zentalis Pharmaceuticals stock traded down $0.12 during trading on Friday, reaching $1.34. 1,017,749 shares of the company traded hands, compared to its average volume of 1,334,899. The firm has a market capitalization of $96.42 million, a PE ratio of -0.54 and a beta of 1.61. The company has a 50 day moving average price of $1.31 and a 200-day moving average price of $2.05. Zentalis Pharmaceuticals, Inc. has a 1-year low of $1.01 and a 1-year high of $9.52.
Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.67). Equities research analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.
Zentalis Pharmaceuticals Profile
(
Free Report)
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.
Featured Stories
Before you consider Zentalis Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zentalis Pharmaceuticals wasn't on the list.
While Zentalis Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
